Welcome to our dedicated page for Voyager Therapeutics SEC filings (Ticker: VYGR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Voyager Therapeutics, Inc. filings document regulatory disclosures for a Nasdaq-listed biotechnology company developing neurotherapeutics for central nervous system diseases. Its Form 8-K reports include quarterly and annual financial results, corporate updates, Regulation FD investor presentations, executive officer transitions and related exhibits covering pipeline and platform information.
Proxy materials describe annual meeting matters such as director elections, advisory executive compensation votes, auditor ratification, charter matters and proposals involving authorized capital. The filing record also identifies Voyager’s common stock, par value and Nasdaq Global Select Market listing, and formalizes governance and capitalization disclosures relevant to its public-company status.
Armistice Capital, LLC and Steven Boyd report ownership of Voyager Therapeutics, Inc. common stock. They beneficially own 3,436,000 shares of common stock, representing 5.58% of the class as of June 30, 2026. They hold shared voting and dispositive power over all 3,436,000 shares, with no sole voting or dispositive power. The shares are directly held by Armistice Capital Master Fund Ltd., for which Armistice Capital acts as investment manager under an Investment Management Agreement. The Master Fund has the right to receive dividends and sale proceeds, while Armistice Capital and Steven Boyd may be deemed to beneficially own the securities through their management roles.
Voyager Therapeutics reported second quarter 2026 results highlighted by continued investment in its neurology pipeline and lower operating expenses. Collaboration revenue was $3.2 million, down from $5.2 million a year earlier, mainly because revenue under the Neurocrine collaboration declined as activities moved beyond the research phase. Research and development expense fell to $22.0 million from $31.3 million, and general and administrative expense decreased to $7.5 million from $10.5 million, reflecting program prioritization and prior restructuring. Net loss narrowed to $24.5 million, or $0.40 per share, from $33.4 million, or $0.57 per share.
Cash, cash equivalents, and marketable securities were $148.8 million as of June 30, 2026. Based on current operating plans and anticipated collaboration reimbursements and interest income, management expects these resources to fund planned operating and capital spending into 2028.
Voyager continues to advance its Alzheimer’s disease programs, with tau-targeted antibody VY7523 expected to deliver tau PET imaging data in the fourth quarter of 2026 and tau-silencing gene therapy VY1706 expected to begin dosing in adults with early Alzheimer’s disease in the same period. Initial acute safety data for VY1706 are targeted for early 2027 and biomarker-based data for the second half of 2027, both subject to enrollment. Partner Neurocrine Biosciences intends to start a clinical trial of Friedreich’s ataxia gene therapy NBIB-‘223 in the second half of 2026, pending FDA IND clearance. Preclinical GLP toxicology data for VY1706 in non-human primates showed it was well tolerated with up to 75% tau reduction in key brain regions after a single IV dose.
Voyager Therapeutics, Inc., a neurology‑focused biotechnology company, reported collaboration revenue of $3.2 million for the quarter ended June 30, 2026, compared with $5.2 million a year earlier. Lower research and development and general and administrative spending reduced the quarterly net loss to $24.5 million from $33.4 million.
As of June 30, 2026, cash, cash equivalents and marketable securities totaled $148.8 million, with total assets of $197.8 million and stockholders’ equity of $154.4 million. The company expects this liquidity to cover planned operating and capital needs for at least twelve months.
Voyager highlights progress in its Alzheimer’s pipeline. VY1706, a tau‑silencing gene therapy, received FDA Investigational New Drug clearance in the second quarter of 2026 and a Health Canada Clinical Trial Application clearance in July 2026, with first dosing in an early Alzheimer’s trial expected in the fourth quarter of 2026 and initial safety data anticipated in early 2027. VY7523, an anti‑tau antibody, is in a Phase 1 multiple‑ascending‑dose study in early Alzheimer’s patients, with initial tau PET imaging efficacy data expected in the fourth quarter of 2026. Multiple CNS gene‑therapy collaborations with Neurocrine, Novartis, Alexion and Transition Bio have provided over $500 million in non‑dilutive funding and could yield up to $6.8 billion in future milestones plus royalties.
Voyager Therapeutics, Inc. is reported as the issuer of common stock in this Schedule 13G/A filing. Investment entities associated with Millennium Management report beneficial ownership of a significant minority stake. Integrated Core Strategies (US) LLC reports beneficial ownership of 4,437,293 shares of common stock, representing 7.3% of the class. Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander each report beneficial ownership of 4,442,951 shares, or 7.4% of the outstanding common stock, with shared voting and dispositive power over these shares and no sole voting or dispositive power. The filing explains that the securities are held by entities subject to voting control and investment discretion of Millennium Management and related managers, and includes a statement that these disclosures should not, by themselves, be construed as an admission of beneficial ownership by Millennium Management LLC, Millennium Group Management LLC, or Mr. Englander.
Voyager Therapeutics, Inc. reported new good laboratory practice toxicology and pharmacology data for VY1706, its investigational tau silencing gene therapy for Alzheimer’s disease. In non-human primates, three- and six-month studies showed a favorable tolerability profile with no adverse clinical pathology or histopathological findings in the central nervous system, dorsal root ganglia, or peripheral organs, including liver, at doses up to 5 x 10^13 vector genomes/kilogram.
The data also showed that a single intravenous dose achieved broad, durable, dose-dependent CNS delivery with up to 75% reduction of MAPT mRNA and tau protein in key Alzheimer’s-relevant brain regions through six months. ALPL, a brain vasculature endothelial receptor, mediated blood-brain barrier transport, supporting potential cross-species translatability. Voyager previously received FDA Investigational New Drug clearance for VY1706 in June 2026 and plans first-in-human dosing in a multi-site, open-label, dose-escalation trial in the second half of 2026.
Voyager Therapeutics director George A. Scangos received a grant of stock options for 30,000 shares of common stock as director compensation. The options have an exercise price of $3.43 per share and expire on June 9, 2036.
According to the company’s 2025 Stock Incentive Plan, all 30,000 underlying shares vest upon the earlier of the one-year anniversary of the grant date or the date of the next annual meeting of stockholders, assuming he continues to serve as a director. After this grant, Scangos holds 30,000 stock options directly.
Voyager Therapeutics, Inc. director Catherine J. Mackey received a grant of stock options to acquire 30,000 shares of common stock. The options have an exercise price of $3.43 per share and expire on June 9, 2036.
According to the company’s 2025 Stock Incentive Plan and director compensation policy, all 30,000 underlying shares vest upon the earlier of the one-year anniversary of the grant date or the next annual stockholder meeting, as long as she continues serving as a director. Following this award, she holds 30,000 options directly from this grant.
Voyager Therapeutics, Inc. reported that director Steven Hyman received a grant of stock options to buy 30,000 shares of common stock at an exercise price of $3.43 per share. The award was made under the company’s 2025 Stock Incentive Plan as part of its director compensation policy.
All 30,000 underlying shares vest upon the earlier of one year from the grant date or the next annual meeting of stockholders, provided he continues to serve as a director. The filing does not show any option exercises or open-market share purchases or sales associated with this grant.
Voyager Therapeutics, Inc. director Nancy Vitale received a grant of stock options covering 30,000 shares of common stock. The options have an exercise price of $3.43 per share and expire on June 9, 2036. All 30,000 underlying shares vest on the earlier of one year from the grant date or the next annual meeting of stockholders, subject to her continued service as a director. Following this grant, she holds options for 30,000 shares directly.
Voyager Therapeutics, Inc. director Michael J. Higgins received a grant of stock options covering 30,000 shares of common stock. The options have an exercise price of 3.43 per share and expire on June 9, 2036.
The award was issued under Voyager’s 2025 Stock Incentive Plan as part of its director compensation policy. All 30,000 underlying shares vest on the earlier of one year from the grant date or the next annual stockholder meeting, if he continues serving as a director.